BioSpace News Archive

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”) today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2023 before the Nasdaq Stock Market opens on Wednesday, April 3, 2024.

In response to the recent safety communications issued by the U.S. Food and Drug Administration regarding concerns over plastic syringes and safety needles manufactured in China, HTL-Strefa Inc.

Florida Cancer Specialists & Research Institute, LLC announced the formation of a new healthcare analytics subsidiary.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) today announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating in the following upcoming conferences.

Aeterna Zentaris Inc. reported its financial and operating results for the year ended December 31, 2023 and provided an update on the completion of enrollment for its ongoing Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency.

Vaxart, Inc. announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt (PC14586) in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type (WT).

Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights.